Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease.

Autor: Lesley Jones, Peter A Holmans, Marian L Hamshere, Denise Harold, Valentina Moskvina, Dobril Ivanov, Andrew Pocklington, Richard Abraham, Paul Hollingworth, Rebecca Sims, Amy Gerrish, Jaspreet Singh Pahwa, Nicola Jones, Alexandra Stretton, Angharad R Morgan, Simon Lovestone, John Powell, Petroula Proitsi, Michelle K Lupton, Carol Brayne, David C Rubinsztein, Michael Gill, Brian Lawlor, Aoibhinn Lynch, Kevin Morgan, Kristelle S Brown, Peter A Passmore, David Craig, Bernadette McGuinness, Stephen Todd, Clive Holmes, David Mann, A David Smith, Seth Love, Patrick G Kehoe, Simon Mead, Nick Fox, Martin Rossor, John Collinge, Wolfgang Maier, Frank Jessen, Britta Schürmann, Reinhard Heun, Heike Kölsch, Hendrik van den Bussche, Isabella Heuser, Oliver Peters, Johannes Kornhuber, Jens Wiltfang, Martin Dichgans, Lutz Frölich, Harald Hampel, Michael Hüll, Dan Rujescu, Alison M Goate, John S K Kauwe, Carlos Cruchaga, Petra Nowotny, John C Morris, Kevin Mayo, Gill Livingston, Nicholas J Bass, Hugh Gurling, Andrew McQuillin, Rhian Gwilliam, Panos Deloukas, Ammar Al-Chalabi, Christopher E Shaw, Andrew B Singleton, Rita Guerreiro, Thomas W Mühleisen, Markus M Nöthen, Susanne Moebus, Karl-Heinz Jöckel, Norman Klopp, H-Erich Wichmann, Eckhard Rüther, Minerva M Carrasquillo, V Shane Pankratz, Steven G Younkin, John Hardy, Michael C O'Donovan, Michael J Owen, Julie Williams

Publikováno v: PLoS ONE, Vol 5, Iss 11, p e13950 (2010)

BackgroundLate Onset Alzheimer's disease (LOAD) is the leading cause of dementia. Recent large genome-wide association studies (GWAS) identified the first strongly supported LOAD susceptibility genes since the discovery of the involvement of APOE in

Externí odkaz: https://doaj.org/article/f60141a186cd4676b259fd600531e266

The Population-Wide Risk-Benefit Profile of Extending the Primary COVID-19 Vaccine Course Compared with an mRNA Booster Dose Program

Autor: Tinevimbo Shiri, Marc Evans, Carla A. Talarico, Angharad R. Morgan, Maaz Mussad, Philip O. Buck, Phil McEwan, William David Strain

Publikováno v: Vaccines, Vol 10, Iss 2, p 140 (2022)

The vaccination program is reducing the burden of COVID-19. However, recently, COVID-19 infections have been increasing across Europe, providing evidence that vaccine efficacy is waning. Consequently, booster doses are required to restore immunity le

Externí odkaz: https://doaj.org/article/207a55762e4547f89156b53e1f284a69

Effects of freezer storage time on levels of complement biomarkers

Autor: Angharad R. Morgan, Caroline O’Hagan, Samuel Touchard, Simon Lovestone, B. Paul Morgan

Publikováno v: BMC Research Notes, Vol 10, Iss 1, Pp 1-5 (2017)

Abstract Background There is uncertainty regarding how stable complement analytes are during long-term storage at – 80 °C. As part of our work program we have measured 17 complement biomarkers (C1q, C1 inhibitor, C3, C3a, iC3b, C4, C5, C9, FB, FD,

Externí odkaz: https://doaj.org/article/501574c0d15e46c4ad3592faa3d140d8

A Narrative Review of Chronic Kidney Disease in Clinical Practice: Current Challenges and Future Perspectives

Autor: Stephen C. Bain, W. David Strain, Martin Whyte, Umesh Dashora, Ruth D. Lewis, Marc Evans, Angharad R. Morgan, Wasim Hanif, Sarah Davies, Dipesh C Patel, Zaheer Yousef

Publikováno v: Advances in Therapy

Chronic kidney disease (CKD) is a complex disease which affects approximately 13% of the world’s population. Over time, CKD can cause renal dysfunction and progression to end-stage kidney disease and cardiovascular disease. Complications associated

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d65f997baac8776dbd9f243bd50d7599
http://europepmc.org/articles/PMC8569052

The role of sodium-glucose co-transporter-2 inhibitors in frail older adults with or without type 2 diabetes mellitus

Autor: Marc Evans, Angharad R Morgan, Sarah Davies, Hannah Beba, William David Strain

Publikováno v: Age and Ageing. 51

Sodium-glucose co-transporter-2 (SGLT2) inhibitors offer significant outcome benefits beyond glucose lowering, including reduced risk of cardiovascular death, all-cause mortality, major adverse cardiovascular events, hospitalisations for heart failur

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7a3fbc69ebcf90a8b3978aaabd59e6c0
https://doi.org/10.1093/ageing/afac201